Life Changing Daily Pill that Fights Cancer and Autoimmune Diseases

Invest Now for a Limited Time

Trethera News

Gloved hand of a scientist in a lab writing on a digital stilus with a digital pen.

Blue DNA illustration

Photo of a series of test tubes.

Scientific microscope with visual representation of DNA helix

Trethera and UCLA Publish Data Demonstrating TRE-515 Ability to Control and Improve Multiple Sclerosis Symptoms in Mouse Models

September 7, 2022

Trethera Receives U.S. Patent Office Notice of Allowance Covering TRE-515 Structural Claims, Extending Protections to Late 2041

August 17, 2022

Trethera Phase 1 Solid Tumors Trial Dose Escalates To Fourth Cohort After Safety Review Committee Determines Primary Trial Endpoint Achieved

Trethera Scientific Founder Dr. Caius Radu To Present Research At Los Angeles Bioscience Ecosystem Summit 2022

Trethera Announces Completion of $3.8 Million Seed Funding Round From Current Investors